A multicenter study on early prediction of antipsychotic response in patients with schizophrenia
- Conditions
- schizophrenia
- Registration Number
- JPRN-UMIN000001862
- Lead Sponsor
- Juntendo University School of Medicine
- Brief Summary
Results At 4 weeks, 81% of risperidone ERs (n=47) achieved >=50% response, whereas only 9% of staying risperidone ENRs (n=11) achieved >=50% response (P<0.0001). In contrast, 58% of olanzapine ERs (n=33) achieved >=50% response, whereas 25% of staying olanzapine ENRs (n=8) achieved >=50% response (P=0.12). Irrespective of the initial antipsychotics, there were no significant differences in outcomes at 4 weeks between staying ENRs and switching ENRs. Conclusion In newly admitted acute schizophrenic patients, non-response to risperidone using CGI-I at 2 weeks can predict subsequent clinical outcomes. However, non-response to olanzapine cannot necessarily be predicted at 2weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 500
Not provided
1) severe liver, renal, respiratory, or cardiac dysfunction 2) diabetes melitus or its history 3) women during pregnancy or nurse, women who want to get pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of remission at 4 weeks after the beginning of antipsychotics
- Secondary Outcome Measures
Name Time Method the Positive and Negative Syndrome Scale (PANSS) ,Clinical Global Impression Change rating scale,Global Assessment of Functioning,the Drug-induced Extrapyramidal Symptom Scale ,blood sugar, total cholesterol, triglyceride